Saniona is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, please visit www.saniona.com (OMX: SANION).
Company Details
- Employees
- 33
- Founded
- -
- Address
- Smedeland, 26b,denmark
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- saniona.com
- HQ
- Glostrup, Hovedstaden
Saniona Questions
Saniona's website is saniona.com
Saniona's LinkedIn profile is https://dk.linkedin.com/company/saniona
Saniona has
33 employees.
View email and phone details for 33
employees at Saniona.
Saniona's industry is
Pharmaceutical Manufacturing
Saniona's top competitors are
Acadia Pharmaceuticals Inc.,
Macure Pharma,
Io Biotech,
Synklino,
Sarepta Therapeutics,
Acesion Pharma,
Contera Pharma,
Aelix Therapeutics,
Scandion Oncology,
Adcendo.
Saniona's categories are Pharmaceutical Manufacturing
Saniona's founding year is 2011
